Retatrutide Research: Phase 2 Data, Mechanism, and the TRIUMPH Program

The research record at a glance

Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide developed by Eli Lilly and Company. It is an investigational drug — not approved by any regulator — currently in the Phase 3 TRIUMPH clinical program. The compound is the subject of multiple published Phase 1 and Phase 2 trials and several recent systematic reviews.

The key pharmacological feature is simultaneous activation of three hormone receptors: GIP (glucose-dependent insulinotropic polypeptide receptor), GLP-1 receptor, and glucagon receptor (GCGR). Earlier incretin agents act on one or two of these; retatrutide acts on all three in a single molecule.

Phase 2 data established: approximately 24% body-weight reduction in obesity at 48 weeks ^[1]; HbA1c reduction of 2.02% in type 2 diabetes at 24 weeks ^[2]; liver-fat reduction of 82.4% in MASLD at 24 weeks ^[5]; a plasma half-life of approximately 6 days ^[4]. Phase 3 trials (obesity, diabetes, cardiovascular, kidney) are ongoing. No approval exists as of 2026.

Triple-agonist mechanism and structural pharmacology

The mechanism of retatrutide rests on three receptor axes.

GLP-1 receptor (GLP-1R). GLP-1 (glucagon-like peptide-1) is an incretin hormone — a gut-derived signal that amplifies insulin secretion after eating. GLP-1R activation suppresses appetite, slows gastric emptying, and promotes glucose-dependent insulin release. This is the axis shared with the single-agonist agents already in clinical use for obesity and diabetes.

GIP receptor (GIPR). GIP (glucose-dependent insulinotropic polypeptide) is a second incretin hormone. GIPR activation enhances postprandial (after-meal) insulin secretion and has direct effects on adipose (fat) tissue. Cryo-EM structural work (Li et al., Cell Discovery, 2024) showed retatrutide is approximately 8.9× more potent at GIPR than native GIP, despite a GIP-based backbone ^[3]. The high GIPR potency is engineered by the C20 fatty-diacid acylation that binds the peptide to albumin for extended half-life — the same structural feature that produces prolonged plasma residence.

Glucagon receptor (GCGR). Glucagon is a pancreatic hormone that raises blood glucose and increases energy expenditure by stimulating hepatic (liver) fat breakdown. Selective GCGR activation in isolation would raise blood glucose — harmful in metabolic disease. In retatrutide, the GLP-1/GIP arms provide insulin-secretion counterbalance, allowing GCGR's energy-expenditure signal to operate without net hyperglycemia. The cryo-EM study found retatrutide is 0.3× as potent at GCGR as native glucagon — a deliberate attenuation that preserves the thermogenic benefit while limiting glucagonergic side effects ^[3].

The three arms signal through cAMP/PKA (cyclic AMP / protein kinase A — a standard intracellular signaling cascade used by hormones to translate an extracellular signal into a cellular response) downstream of all three class-B GPCRs. The triple cAMP signal is additive, which researchers believe underpins the efficacy step-change versus dual or single agonists ^[6].

A 2025 review (Drucker DJ et al., Diabetes Care) noted that retatrutide and similar new molecular entities exhibit unique PK/PD (pharmacokinetic/pharmacodynamic — how the drug moves through the body and what it does) profiles compared with first-generation GLP-1 agents, reflecting simultaneous glucagon and GLP-1 activation ^[8].

Phase 2 clinical outcomes

Obesity (Jastreboff et al., NEJM, 2023). 338 adults with BMI ≥30 or ≥27 plus comorbidity received once-weekly subcutaneous retatrutide at 1, 4, 8, or 12 mg over 48 weeks. At 12 mg, mean body-weight change was −24.2% versus −2.1% with placebo. GI adverse events were dose-related and predominantly mild-to-moderate. A dose-dependent heart-rate increase peaked at approximately week 24 ^[1].

Type 2 diabetes (Rosenstock et al., Lancet, 2023). 281 adults received once-weekly retatrutide 0.5–12 mg with stepwise dose escalation. At 12 mg and 24 weeks: HbA1c −2.02% (placebo −0.01%); body weight −16.94% at 36 weeks (placebo −3.00%). Mild-to-moderate GI adverse events in 35% of participants; no severe hypoglycemia; no deaths ^[2].

MASLD substudy (Sanyal et al., Nature Medicine, 2024). 98 participants with ≥10% liver fat by MRI-PDFF and no type 2 diabetes. Retatrutide 12 mg: relative liver-fat change −82.4% at 24 weeks (placebo +0.3%); 86% reached normal liver fat (<5%) at 24 weeks; reduction sustained to −86.0% at 48 weeks ^[5].

Phase 1b first-in-human pharmacokinetics (Urva et al., Lancet, 2022). 72 adults with type 2 diabetes received single/multiple ascending doses. Half-life approximately 6 days. Placebo-adjusted weight loss −8.96 kg (90% CI −11.16 to −6.75) at highest dose over 12 weeks. Treatment-emergent adverse events in 63%, mostly GI; acceptable safety profile ^[4].

Retatrutide results summary: across the Phase 2 program, the compound reduced body weight, HbA1c, and liver fat in three separate randomized controlled trials — the strongest clinical evidence package any investigational incretin agent has assembled to date.

Phase 3 TRIUMPH program

The ongoing Phase 3 program is designated TRIUMPH. Trials include:

• TRIUMPH-1 and TRIUMPH-2: obesity (BMI ≥30) without and with type 2 diabetes
• TRIUMPH-3: obesity with established cardiovascular disease
• Cardiovascular outcomes (NCT06383390): dedicated MACE (major adverse cardiovascular event) endpoint study
• Kidney outcomes (TRANSCEND-CKD, NCT05929066): chronic kidney disease population
• CKD-related metabolic endpoints (NCT05931367)
• Additional endpoints (NCT05882045)
• Active comparator vs tirzepatide (a dual GIP/GLP-1 agonist)

A 2025 systematic review of 53 phase 2 and 3 obesity trials confirmed retatrutide among 14 agents in active phase 3 programs ^[11]. A 2025 pipeline review (Madsbad et al., Expert Opinion on Investigational Drugs) identified slow up-titration as the key strategy for managing GI adverse-event burden in the class, with retatrutide's phase 3 design incorporating this learning ^[12].

A comprehensive 2026 overview (Panou et al., Expert Review of Clinical Pharmacology) reported efficacy figures from the full Phase 2 dataset: HbA1c reduction up to 2.16%, weight loss up to 26.56%, with GI event rates linked to the escalation rate and starting dose ^[15]. The long-term cardiovascular and renal outcomes remain outstanding.

Retatrutide vs tirzepatide

Tirzepatide is a dual GIP/GLP-1 agonist approved by the FDA for type 2 diabetes and obesity. Retatrutide adds a third receptor arm — glucagon — which tirzepatide does not activate.

In Phase 2, the highest retatrutide dose (12 mg, 48 weeks) produced approximately 24.2% weight loss; the highest tirzepatide phase 3 dose (15 mg, 72 weeks) produced approximately 22.5% weight loss in the SURMOUNT-1 trial. Direct comparison is not valid across different trial populations and durations — the TRIUMPH program includes an active-comparator trial versus tirzepatide specifically to answer the head-to-head question.

The mechanistic difference (triple vs dual agonism) is not a claim of superiority — it is a pharmacological distinction whose clinical significance will be determined by Phase 3. The 2025 Biomolecules review (Katsi et al.) characterized the weight-loss profile as a 'step-change' relative to prior incretin agents, but noted that the GI and heart-rate safety profile is the key tradeoff ^[6].

Key distinction: tirzepatide is approved; retatrutide is not. Use of unapproved retatrutide carries all the regulatory and safety uncertainties described in the effects and dosage pages.

Retatrutide Retatrutide references are indexed on the references page.

Retatrutide side effects

The principal adverse effects documented in Phase 2 clinical trials:

Gastrointestinal. Nausea, vomiting, diarrhea, and constipation — dose-related, predominantly mild-to-moderate, most pronounced during dose escalation. Up to 45% of participants at the highest dose experienced nausea; the 18% discontinuation rate at 12 mg was primarily GI-driven ^[1]. Retatrutide delays gastric emptying, a mechanism confirmed in a 2023 study by Urva et al. ^[9], which underlies both the nausea and the sulfur-burp pattern widely reported in community settings.

Heart rate. A dose-dependent increase in resting heart rate was observed in Phase 2, peaking at approximately week 24. Mean increases were approximately 5–7 bpm at the highest doses ^[1]. The glucagon receptor arm is the primary driver of this chronotropic (heart-rate-increasing) effect via cAMP/PKA cardiac signaling. A dedicated cardiovascular outcomes trial is ongoing.

Injection-site reactions. Approximately 8% of Phase 2 participants reported mild local reactions at the injection site ^[1].

Lean-mass reduction. Body-composition data confirm absolute lean-mass loss alongside fat-mass loss, though the fat-to-lean ratio is more favorable than historic bariatric benchmarks ^[14].

Dysesthesia (burning or tingling skin sensations). A 2026 pharmacovigilance analysis (Laroche et al., EJCP) identified dysesthesia as a class-level signal for GLP-1R-based agents in the VigiBase adverse-event database — an under-recognized adverse event beyond GI symptoms ^[13].